Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Modifying the Medical Research Council grading system through Rasch analyses.

Vanhoutte EK, Faber CG, van Nes SI, Jacobs BC, van Doorn PA, van Koningsveld R, Cornblath DR, van der Kooi AJ, Cats EA, van den Berg LH, Notermans NC, van der Pol WL, Hermans MC, van der Beek NA, Gorson KC, Eurelings M, Engelsman J, Boot H, Meijer RJ, Lauria G, Tennant A, Merkies IS; PeriNomS Study Group.

Brain. 2012 May;135(Pt 5):1639-49. doi: 10.1093/brain/awr318. Epub 2011 Dec 20.

2.

Prediction of respiratory insufficiency in Guillain-Barré syndrome.

Walgaard C, Lingsma HF, Ruts L, Drenthen J, van Koningsveld R, Garssen MJ, van Doorn PA, Steyerberg EW, Jacobs BC.

Ann Neurol. 2010 Jun;67(6):781-7. doi: 10.1002/ana.21976.

PMID:
20517939
3.

IVIG treatment and prognosis in Guillain-Barré syndrome.

van Doorn PA, Kuitwaard K, Walgaard C, van Koningsveld R, Ruts L, Jacobs BC.

J Clin Immunol. 2010 May;30 Suppl 1:S74-8. doi: 10.1007/s10875-010-9407-4. Review.

4.

Pain accompanies pure motor Guillain-Barré syndrome.

Ruts L, Rico R, van Koningsveld R, Botero JD, Meulstee J, Gerstenbluth I, Merkies IS, van Doorn PA.

J Peripher Nerv Syst. 2008 Dec;13(4):305-6. doi: 10.1111/j.1529-8027.2008.00197.x. No abstract available.

PMID:
19192071
5.

Recurrent Guillain-Barré syndrome.

Kuitwaard K, van Koningsveld R, Ruts L, Jacobs BC, van Doorn PA.

J Neurol Neurosurg Psychiatry. 2009 Jan;80(1):56-9. doi: 10.1136/jnnp.2008.156463. Epub 2008 Oct 17.

PMID:
18931012
6.

Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study.

Garssen MP, van Koningsveld R, van Doorn PA, Merkies IS, Scheltens-de Boer M, van Leusden JA, van Schaik IN, Linssen WH, Visscher F, Boon AM, Faber CG, Meulstee J, Prick MJ, van den Berg LH, Franssen H, Hiel JA, van den Bergh PY, Sindic CJ.

J Neurol Neurosurg Psychiatry. 2007 Sep;78(9):1012-3. No abstract available. Erratum in: J Neurol Neurosurg Psychiatry. 2007 Dec;78(12):1416. Merkies, ISJ [added]; Scheltens-de Boer M [added]; van Leusden, JA [added]; van Schaik, IN [added]; Linssen, WHJP [added]; Visscher, F [added]; Boon, AM [added]; Faber, CG [added]; Meulstee, J [added]; Prick, MJJ [added]; van den Berg, LH [added]; Franssen.

7.

Hypoxia induces epidermal keratinocyte matrix metalloproteinase-9 secretion via the protein kinase C pathway.

O'Toole EA, van Koningsveld R, Chen M, Woodley DT.

J Cell Physiol. 2008 Jan;214(1):47-55.

PMID:
17559070
8.

A clinical prognostic scoring system for Guillain-Barré syndrome.

van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC.

Lancet Neurol. 2007 Jul;6(7):589-94.

PMID:
17537676
9.

Determination of pain and response to methylprednisolone in Guillain-Barré syndrome.

Ruts L, van Koningsveld R, Jacobs BC, van Doorn PA.

J Neurol. 2007 Oct;254(10):1318-22. Epub 2007 Apr 11.

10.

Immunotherapy for Guillain-Barré syndrome: a systematic review.

Hughes RA, Swan AV, Raphaël JC, Annane D, van Koningsveld R, van Doorn PA.

Brain. 2007 Sep;130(Pt 9):2245-57. Epub 2007 Mar 2. Review.

PMID:
17337484
11.

Residual fatigue is independent of antecedent events and disease severity in Guillain-Barré syndrome.

Garssen MP, Van Koningsveld R, Van Doorn PA.

J Neurol. 2006 Sep;253(9):1143-6. Epub 2006 Sep 22.

PMID:
16998652
12.

Corticosteroids for Guillain-Barré syndrome.

Hughes RA, Swan AV, van Koningsveld R, van Doorn PA.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD001446. Review. Update in: Cochrane Database Syst Rev. 2010;(2):CD001446.

PMID:
16625544
13.

Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations.

Ruts L, van Koningsveld R, van Doorn PA.

Neurology. 2005 Jul 12;65(1):138-40.

PMID:
16009902
14.

Steroids in the Guillain-Barré syndrome: is there a therapeutic window?

Van Koningsveld R, Van Doorn PA.

Neurologia. 2005 Mar;20(2):53-7. No abstract available.

PMID:
15726470
15.

HLA class II alleles are not a general susceptibility factor in Guillain-Barré syndrome.

Geleijns K, Schreuder GM, Jacobs BC, Sintnicolaas K, van Koningsveld R, Meulstee J, Laman JD, van Doorn PA.

Neurology. 2005 Jan 11;64(1):44-9.

PMID:
15642902
16.

Immunotherapy for Guillain-Barré syndrome.

van Doorn PA, van Koningsveld R.

Lancet Neurol. 2004 Feb;3(2):84. Review. No abstract available.

PMID:
14746999
17.

Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.

van Koningsveld R, Schmitz PI, Meché FG, Visser LH, Meulstee J, van Doorn PA; Dutch GBS study group.

Lancet. 2004 Jan 17;363(9404):192-6.

PMID:
14738791
18.

Risk factors associated with Campylobacter jejuni infections in Curaçao, Netherlands Antilles.

Endtz HP, van West H, Godschalk PC, de Haan L, Halabi Y, van den Braak N, Kesztyüs BI, Leyde E, Ott A, Verkooyen R, Price LJ, Woodward DL, Rodgers FG, Ang CW, van Koningsveld R, van Belkum A, Gerstenbluth I.

J Clin Microbiol. 2003 Dec;41(12):5588-92.

19.

Cross-reactive anti-galactocerebroside antibodies and Mycoplasma pneumoniae infections in Guillain-Barré syndrome.

Ang CW, Tio-Gillen AP, Groen J, Herbrink P, Jacobs BC, Van Koningsveld R, Osterhaus AD, Van der Meché FG, van Doorn PA.

J Neuroimmunol. 2002 Sep;130(1-2):179-83.

PMID:
12225900
20.

Infections and course of disease in mild forms of Guillain-Barré syndrome.

Van Koningsveld R, Schmitz PI, Ang CW, Groen J, Osterhaus AD, Van der Meché FG, Van Doorn PA.

Neurology. 2002 Feb 26;58(4):610-4.

PMID:
11865140
21.

Gastroenteritis-associated Guillain-Barré syndrome on the Caribbean island Curaçao.

van Koningsveld R, Rico R, Gerstenbluth I, Schmitz PI, Ang CW, Merkies IS, Jacobs BC, Halabi Y, Endtz HP, van der Meché FG, van Doorn PA.

Neurology. 2001 Jun 12;56(11):1467-72.

PMID:
11402102
22.

Changes in referral pattern and its effect on outcome in patients with Guillain-Barré syndrome.

Van Koningsveld R, Van Doorn PA, Schmitz PI, Van der Meché FG.

Neurology. 2001 Feb 27;56(4):564-6.

PMID:
11222810
23.

Health burden in the Netherlands due to infection with thermophilic Campylobacter spp.

Havelaar AH, de Wit MA, van Koningsveld R, van Kempen E.

Epidemiol Infect. 2000 Dec;125(3):505-22.

24.

A case of Guillain-Barré syndrome following a family outbreak of Campylobacter jejuni enteritis.

Ang CW, van Doorn PA, Endtz HP, Merkies IS, Jacobs BC, de Klerk MA, van Koningsveld R, van der Meché FG.

J Neuroimmunol. 2000 Nov 1;111(1-2):229-33.

PMID:
11063843
25.

IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barré syndrome.

van der Pol WL, van den Berg LH, Scheepers RH, van der Bom JG, van Doorn PA, van Koningsveld R, van den Broek MC, Wokke JH, van de Winkel JG.

Neurology. 2000 Apr 25;54(8):1661-5.

PMID:
10762510
26.

Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands.

Van Koningsveld R, Van Doorn PA, Schmitz PI, Ang CW, Van der Meché FG.

Neurology. 2000 Feb 8;54(3):620-5.

PMID:
10680793
27.

Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. European Inflammatory Neuropathy Cause and Treatment (INCAT) group.

Martina IS, van Koningsveld R, Schmitz PI, van der Meché FG, van Doorn PA.

J Neurol Neurosurg Psychiatry. 1998 Nov;65(5):743-7.

Supplemental Content

Loading ...
Support Center